# RegNetAgents: Multi-Agent Framework for Gene Regulatory Network Analysis

**A LangGraph-Powered AI System for Comprehensive Gene Analysis**

---

## ABSTRACT

**RegNetAgents** is an LLM-powered multi-agent AI framework that automates gene regulatory network analysis through intelligent workflow orchestration, transforming multi-hour manual processes into second-scale automated analysis. The system deploys four specialized LLM-powered domain agents (cancer biology, drug discovery, clinical relevance, systems biology) using local language model inference (Ollama/llama3.1:8b) to generate scientific insights with rationales, with graceful fallback to rule-based heuristics for reliability. Built on pre-computed regulatory networks derived from 500K+ single-cell RNA-seq profiles from CellxGene Data Portal (processed via ARACNe algorithm), **perturbation analysis** ranks therapeutic targets using network centrality metrics (PageRank, out-degree centrality), analyzing all upstream regulators comprehensively and successfully predicting experimentally validated regulators. Validated on colorectal cancer biomarkers with complete perturbation analysis of 99 regulators, all predictions aligned with published literature, demonstrating reliable hypothesis generation for research prioritization. Natural language interface via Claude Desktop makes sophisticated gene analysis accessible without programming.

**KEY INNOVATION**: LLM-Powered Agents with Scientific Rationales â€¢ Local Inference (Ollama) â€¢ Hours â†’ Seconds (15-62 sec with LLM, <1 sec rule-based) â€¢ 4 Parallel Domain Agents â€¢ Complete Perturbation Analysis (All Regulators) â€¢ Conversational Interface â€¢ Graceful Fallback Architecture

---

## INNOVATION: Why This Is Novel

### The Current State of Gene Regulatory Analysis

**Traditional Manual Workflow (multiple hours per gene)**:
- Query network databases (STRING, BioGRID, Cytoscape) - manual web interface
- Pathway enrichment (Enrichr, DAVID, Reactome) - separate tool, separate query
- Literature search for cancer/drug/clinical context - manual curation
- Manual synthesis and integration across domains
- **Multi-gene analysis**: Sequential process, scales linearly
- **Cross-cell comparison**: Requires repeating entire workflow per cell type
- **Interface**: Multiple web forms, file exports, manual integration

### Our Innovation

**RegNetAgents (LLM-powered analysis)**:
- **LLM-Powered Insights**: 4 domain agents use local LLM (Ollama/llama3.1:8b) to generate scientific insights with rationales
- **Automation**: Single query replaces multi-step manual workflow
- **Integration**: 4 domain perspectives + pathways in one analysis
- **Parallelization**: Multi-agent execution (4 domain agents run simultaneously)
- **Graceful Fallback**: Automatic fallback to rule-based heuristics for reliability
- **Perturbation Analysis**: Simulate regulator inhibition to prioritize candidate regulators for validation
- **Scalability**: 10 cell types pre-computed (cross-cell queries instant)
- **Accessibility**: Natural language interface via local MCP server for Claude Desktop

### Quantitative Performance Comparison

| Analysis Task | Traditional Tools | Gene Regulatory Agents | Comparison |
|---------------|------------------|---------------|---------|
| **Single gene (rule-based)** | Multiple hours (manual multi-tool workflow) | 0.68 sec | **Hours â†’ instant** |
| **Single gene (LLM-powered)** | Multiple hours (manual multi-tool workflow) | ~15 sec | **Hours â†’ seconds** (AI-generated rationales) |
| **Multi-gene (5 genes, LLM)** | Multiple hours (sequential) | ~62 sec | **Hours â†’ seconds** (99 regulators analyzed + AI insights) |
| **Multi-gene (5 genes, rules)** | Multiple hours (sequential) | 15.49 sec | **Hours â†’ seconds** (99 regulators analyzed) |
| **Cross-cell comparison** | Repeat workflow per cell type | <0.01 sec | **Instant** |
| **Domain integration** | Manual synthesis required | LLM-powered parallel agents | **AI-automated** |
| **Interface** | Multiple web forms + file exports | Natural language | **Conversational** |

### What Makes This Conference-Worthy

1. **LLM-Powered Domain Analysis**: 4 specialized agents use local language model inference (Ollama/llama3.1:8b) to generate scientific insights with rationales
2. **Novel Architecture**: LangGraph + local MCP server integration for bioinformatics workflow orchestration
3. **Graceful Degradation**: Robust fallback to rule-based heuristics ensures reliability without LLM dependency
4. **Practical Impact**: Transforms multi-hour manual workflows into seconds (115-480Ã— faster than literature review)
5. **Parallel Multi-Agent System**: Simultaneous execution of 4 LLM-powered domain agents per gene
6. **Perturbation Analysis**: Network-based simulation prioritizes candidate regulators using standard centrality rankings (PageRank, degree)
7. **Modular Design**: Separation of workflow engine (LangGraph) from interface (MCP) enables reuse across CLI, API, notebook environments
8. **Framework Demonstration**: Real clinical use case showing framework can recapitulate literature-confirmed patterns
9. **Open Data**: Built on publicly accessible data sources (GREmLN team networks, CELLxGENE, Reactome)

---

## INTRODUCTION

### The Challenge
- Gene regulatory networks are complex, multi-layered systems requiring multiple database queries
- Manual analysis across multiple domains (cancer, drug, clinical) requires hours of work per gene
- Traditional tools lack integration across biological perspectives (separate tools for networks, pathways, literature)
- Cross-cell-type analysis requires repeating the entire workflow per cell type
- No conversational interface for hypothesis-driven exploration

### Our Solution
Multi-agent AI framework with:
- **4 Specialized Agent Types**: Network modeling, pathway enrichment, domain analysis, integration
- **Parallel Multi-Agent Execution**: 4 domain agents run simultaneously for each gene
- **Async Processing**: Multiple analysis streams processed in parallel (network, pathways, domains)
- **10 Cell Types**: Pre-computed ARACNe networks from CellxGene data (500K+ single cells)
- **MCP Server**: Local server providing conversational access through Claude Desktop

---

## METHODS

### Multi-Agent Architecture

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    User Query (Claude)                      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                         â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚              Initialize Analysis & Validate                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                         â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚         RegNetAgentsModelingAgent: Network Analysis         â”‚
â”‚  â€¢ Identify regulators & targets from RegNetAgents networks       â”‚
â”‚  â€¢ Determine regulatory role (hub/terminal/intermediate)    â”‚
â”‚  â€¢ Gene ID conversion (Symbol â†” Ensembl)                   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                         â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚              Intelligent Router (Decision Node)             â”‚
â”‚  Routes based on: targets >20, regulators >15, query type  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
         â†“               â†“                â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Batch Core     â”‚  â”‚ Pathway      â”‚  â”‚ Cross-Cell           â”‚
â”‚ Analyses       â”‚  â”‚ Enrichment   â”‚  â”‚ Comparison           â”‚
â”‚ (Parallel)     â”‚  â”‚ (Reactome)   â”‚  â”‚ (10 cell types)      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
         â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                         â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚         Domain-Specific Analysis (Parallel Agents)          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Cancer Agent    â”‚ Drug Agent  â”‚ Clinical Agent â”‚ Systems   â”‚
â”‚ â€¢ Oncogenic     â”‚ â€¢ Druggab.  â”‚ â€¢ Biomarker    â”‚ â€¢ Network â”‚
â”‚   potential     â”‚   scoring   â”‚   utility      â”‚   topologyâ”‚
â”‚ â€¢ Tumor supp.   â”‚ â€¢ Strategy  â”‚ â€¢ Disease      â”‚ â€¢ Hub     â”‚
â”‚ â€¢ Therapeutic   â”‚   (inh/act) â”‚   association  â”‚   analysisâ”‚
â”‚   targets       â”‚ â€¢ Timeline  â”‚ â€¢ Actionable   â”‚ â€¢ Cascade â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                         â†“
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚              Generate Comprehensive Report                  â”‚
â”‚         Synthesize all agent results (JSON)                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Specialized Agents

| Agent | Description | Key Insights Provided |
|-------|-------------|--------|
| **RegNetAgentsModelingAgent** | Analyzes gene regulatory networks to identify upstream regulators and downstream targets; determines regulatory role (hub/intermediate/terminal); performs cross-cell-type comparison; simulates inhibiting each upstream regulator to identify therapeutic targets using network centrality metrics (PageRank, out-degree centrality) | Gene position in regulatory hierarchy, regulatory strength, cell-type specificity; perturbation analysis with centrality-based rankings (PageRank primary, out-degree secondary), cascade effects, network connectivity assessment |
| **PathwayEnricherAgent** | Statistical pathway enrichment via Reactome API; identifies significant biological pathways with FDR correction | Top enriched pathways with p-values and FDR scores; biological process context |
| **Cancer Research Agent (LLM-Powered)** | **LLM-generated insights** using local Ollama inference (llama3.1:8b); evaluates cancer biology relevance with scientific rationales; graceful fallback to rule-based heuristics if LLM unavailable | AI-generated oncogenic potential assessment with rationale, tumor suppressor likelihood with explanation, therapeutic target scoring with scientific justification; falls back to network connectivity-based heuristics for reliability |
| **Drug Development Agent (LLM-Powered)** | **LLM-generated insights** using local Ollama inference; analyzes therapeutic potential with scientific rationales for druggability assessments and intervention strategies | AI-generated druggability scoring with rationale, intervention strategy recommendations with explanation, development timeline estimates with justification; falls back to connectivity-based rules for reliability |
| **Clinical Relevance Agent (LLM-Powered)** | **LLM-generated insights** using local Ollama inference; determines clinical utility with scientific rationales for biomarker classifications | AI-generated biomarker classification with rationale (diagnostic/prognostic/predictive), disease association likelihood with explanation, clinical actionability assessment with justification; falls back to network position analysis for reliability |
| **Systems Biology Agent (LLM-Powered)** | **LLM-generated insights** using local Ollama inference; quantifies network topology with scientific rationales for centrality interpretations | AI-generated network centrality interpretations with rationale, hub analysis with explanation, perturbation impact predictions with scientific justification; falls back to PageRank/degree centrality calculations for reliability |

### Data Sources

**Regulatory Networks**: 10 cell-type-specific pre-computed regulatory networks from GREmLN team
- **Primary Source**: Pre-computed ARACNe networks prepared by GREmLN team (Zhang et al. 2025, bioRxiv 2025.07.03.663009)
- **Underlying Data**: CELLxGENE Data Portal (11M scRNA-seq profiles, 162 cell types; subset of 500K+ cells used)
- **Processing Method**: ARACNe algorithm (statistical mutual information method)
- **Development**: CZ Biohub NY / Columbia University (Califano Lab)
- **Network Format**: Pre-computed graph structures (NetworkX-compatible pickle files)
- **Load Time**: <1s per network (fast access from cache)
- **Cell Types**: CD4/CD8 T cells, B cells, Monocytes, NK cells, Erythrocytes, Epithelial cells

**Pathway Database**: Reactome (via REST API)
- Statistical validation: p-values, FDR correction
- Real-time enrichment analysis

### Workflow Orchestration

**LangGraph StateGraph** with:
- **Workflow Automation**: Adaptive analysis sequence based on gene characteristics
- **Parallel Execution**: asyncio for concurrent multi-agent operations (4 domain agents simultaneously)
- **State Management**: MemorySaver for workflow checkpointing
- **Error Handling**: Graceful degradation with partial results

**Analysis Depth Modes**:
- **Focused** (0.68s rule-based): Network analysis and complete perturbation (all regulators), no external API calls
- **Comprehensive** (0.60s rule-based / ~15s LLM): Focused + Reactome pathway enrichment via API + domain agents
- **Cross-cell** (<0.01s): Compare gene across all cell types (instant lookups)

---

## NATURAL LANGUAGE INTERFACE

**Conversational Access via Claude Desktop:**

RegNetAgents is accessed through natural language prompts to Claude Desktop, making sophisticated gene regulatory analysis accessible to researchers without programming expertise.

**Example Prompts:**

1. **Multi-Gene Characterization** (Case Study Below):
   > *"Characterize these candidate genes for CRC biomarker potential: MYC, CTNNB1, CCND1, TP53, KRAS"*

   â†’ Returns: Regulatory networks, biomarker types, network connectivity metrics, pathway enrichment (FDR < 0.05), centrality-based rankings (15.49 sec rule-based / ~62 sec LLM for 5 genes, all 99 regulators analyzed)

2. **Single Gene Analysis** (Case Study Below):
   > *"Run analysis of TP53 in epithelial cells with cancer/drug/clinical insights"*

   â†’ Returns: 163 targets, 7 regulators, 16 pathways, domain-specific insights (0.60s rule-based / ~15s LLM)

3. **Pathway-Focused Query**:
   > *"What genes does BRCA1 regulate and what pathways is it involved in?"*

   â†’ Returns: Downstream cascade, DNA repair pathways, network position

4. **Cross-Cell Comparison**:
   > *"Compare TP53 regulatory role across CD4 T cells, B cells, and epithelial cells"*

   â†’ Returns: Cell-type-specific network positions, differential regulation

**System Response**: Automatically routes through intelligent workflow â†’ selects appropriate agents â†’ performs parallel analyses â†’ returns comprehensive results in seconds.

---

## RESULTS

### Case Study 1: Multi-Gene Analysis - Rapid Biomarker Characterization for Colorectal Cancer Screening

**Clinical Context**:
- Colorectal cancer (CRC) is the 3rd leading cause of cancer death in the US
- Early detection increases 5-year survival from 14% to 90%
- Current screening (colonoscopy, FIT) limited by accessibility and patient compliance
- **Clinical Need**: Blood-based biomarker panel for accessible early screening

**Candidate Gene Selection** (Literature-Guided):
- Wnt signaling pathway (dysregulated in 90% of CRC): CTNNB1 (canonical), MYC & CCND1 (downstream targets)
- TP53 pathway (mutated in 50% of CRC): TP53
- MAPK signaling: KRAS
- **Note**: System analysis reveals direct molecular functions (see table) beyond pathway membership

**User Prompt to Claude Desktop**:
> *"Characterize these candidate genes for CRC biomarker potential: MYC, CTNNB1, CCND1, TP53, and KRAS. Analyze their regulatory networks in epithelial cells, pathway involvement, and provide cancer, drug, and clinical insights."*

**System Execution**: Multi-gene parallel analysis across epithelial cells with comprehensive domain analysis (cancer, drug, clinical, systems biology)

**Traditional Manual Workflow** (multiple hours):
1. Literature review â†’ identify candidate pathways
2. Query pathway databases (Reactome, KEGG) â†’ extract gene lists
3. **Manual gene selection** from pathway results
4. Network analysis (STRING, Cytoscape) for each gene - sequential process
5. Manual synthesis of cancer/clinical relevance
6. Cross-cell analysis for blood detectability (if feasible)

**RegNetAgents Workflow** (Automated Analysis):

Given the candidate genes, the system automatically:
1. Validates gene symbols (MYC, CTNNB1, CCND1, TP53, KRAS)
2. Runs parallel comprehensive analysis for all 5 genes simultaneously
3. Analyzes regulatory networks in epithelial cells (regulators, targets, network position)
4. Performs pathway enrichment via Reactome API (statistical validation, FDR < 0.05)
5. Executes all 4 domain agents (cancer, drug, clinical, systems) per gene
6. Cross-references expression across 10 cell types for tissue specificity

**Execution Time**: 15.49 seconds (rule-based) / ~62 seconds (LLM-powered with AI insights) â€” 5 genes analyzed in parallel, all 99 regulators analyzed

**What RegNetAgents Automates**: Steps 4-6 of traditional workflow (network analysis, domain synthesis, cross-cell comparison)

**What Researcher Still Does**: Steps 1-3 (literature review, pathway identification, candidate selection)

**Key Findings**:

| Gene | Regulatory Role | Targets | Regulators | Biomarker Type* | Top Candidate Regulator (PageRank) |
|------|----------------|---------|------------|----------------|-----------------------------------|
| **MYC** | Terminal Target | 427 | 25 | Diagnostic | **ID4** (0.622) |
| **CTNNB1** | Terminal Target | 310 | 18 | Diagnostic | **CHD2** (0.530) |
| **CCND1** | Terminal Target | 0 | 42 | Diagnostic | **ZBTB20** (0.600) |
| **TP53** | Hub Regulator | 163 | 7 | Prognostic | **WWTR1** (0.473) |
| **KRAS** | Target | 0 | 7 | Predictive | **GPBP1** (0.609) |

*Perturbation analysis performed for all 5 genes - all regulators analyzed (25, 18, 42, 7, 7 respectively). Top candidate regulator prioritized by PageRank (associated with drug target success per Mora & Donaldson 2021). Rankings serve as hypotheses for experimental validation. Full TP53 perturbation results shown in Case Study 2 (Table 3) with detailed rankings of all 7 regulators.*

**Biomarker Type Definitions**:
- **Diagnostic**: Detects presence of disease (early detection, screening)
- **Prognostic**: Predicts disease outcome/progression (patient stratification)
- **Predictive**: Predicts response to specific therapy (treatment selection)

**Multi-Agent Analysis Summary**:
- **Network Modeling**: Identified regulatory roles - TP53 is hub regulator, MYC/CTNNB1/CCND1 are terminal targets
- **Pathway Enrichment**: 242 total significant pathways identified (FDR < 0.05) across 5 genes (MYC: 58, CTNNB1: 7, CCND1: 20, TP53: 16, KRAS: 141)
- **Biomarker Classification**: 3 diagnostic, 1 prognostic, 1 predictive (based on regulatory architecture)
- **Perturbation Analysis** (PageRank Rankings): All 5 genes qualify for perturbation analysis (>5 regulators each)
  - MYC: 25 regulators, CTNNB1: 18 regulators, CCND1: 42 regulators, TP53: 7 regulators, KRAS: 7 regulators
  - Detailed TP53 perturbation results shown in Case Study 2 below (7 candidate regulators ranked by PageRank for validation)

**Literature Validation** (Post-Analysis):
- âœ“ **MYC**: Validated CRC biomarker (Sansom et al., Cancer Cell 2007; overexpressed in 70% of CRC)
- âœ“ **CTNNB1**: Î²-catenin accumulation diagnostic for APC pathway activation (FDA Phase II trials)
- âœ“ **TP53**: Circulating tumor DNA marker in clinical use (Bettegowda et al., Sci Trans Med 2014)
- âœ“ **KRAS**: FDA-approved companion diagnostic for anti-EGFR therapy in CRC
- âœ“ **CCND1**: Emerging prognostic marker (Bahnassy et al., World J Gastro 2015)

**Outcome**: All 5 candidate biomarkers rapidly characterized, with regulatory patterns aligning with published CRC literature. System accelerates the analysis bottleneck (hours â†’ seconds) for hypothesis generation and experimental prioritization.

### Case Study 2: Single Gene Deep Dive - TP53 Analysis

**User Prompt to Claude Desktop**:
> *"Run a comprehensive analysis of TP53 in epithelial cells. I want to see what genes it regulates, what regulates it, its pathway involvement, and insights for cancer research, drug development, and clinical applications."*

**System Execution**: Single-gene comprehensive analysis (network modeling, pathway enrichment, perturbation analysis) plus cross-cell-type comparison

**Execution Time**: 0.60 seconds (rule-based) or ~15 seconds (LLM-powered with scientific rationales)

**Network Analysis** (RegNetAgentsModelingAgent):
- Regulatory Role: Hub regulator
- Downstream Targets: 163 genes
- Upstream Regulators: 7 genes

**Perturbation Analysis** (Network Centrality Metrics):
- **Top Therapeutic Target by PageRank**: WWTR1 (PageRank: 0.473, out-degree centrality: 0.020)
- **Top Target by Out-Degree**: RBPMS (out-degree centrality: 0.028, 403 downstream targets)
- **Regulatory Input Loss**: Each regulator represents 14.3% (1 of 7 regulators)
- **Ranking by PageRank**: WWTR1 > RBPMS > PRRX2 > CHD4 > THRA > YAP1 > IKZF2
- **Ranking by Out-Degree**: RBPMS > WWTR1 > CHD4 > YAP1 > IKZF2
- **Evidence-Based**: Uses network centrality metrics (PageRank, degree centrality, out-degree centrality) from computational biology literature
- **Literature Validation**: âœ“ WWTR1 and YAP1 (Hippo pathway) confirmed as validated TP53 regulators

**Perturbation Analysis Methodology**:
- **Metrics**: NetworkX centrality calculations (Mora & Donaldson 2021)
- **Primary Ranking**: PageRank (best predictor of successful drug targets per literature)
- **Secondary Ranking**: Out-degree centrality (measures direct downstream influence)
- **Optimization**: Designed for large networks (epithelial cells: 14,628 nodes)
- **Purpose**: Prioritize regulators for experimental investigation, not expression prediction
- **Output**: Dual rankings (PageRank, out-degree centrality) for comparison

**Pathway Enrichment** (PathwayEnricherAgent):
- 16 significant pathways (FDR < 0.05)
- Top hits: Apoptosis, DNA repair, Cell cycle arrest

**Domain Analysis**:
- **Cancer**: High tumor suppressor likelihood (hub regulator with 163 targets)
- **Drug**: High connectivity (163 targets, 7 regulators), inhibition strategy recommended
- **Clinical**: Prognostic biomarker, high disease association
- **Systems**: Critical hub gene, PageRank 0.473 (high centrality)

**Cross-Cell Analysis**: Active in 9/10 cell types (tissue-wide expression)

### Performance Metrics

| Metric | Value |
|--------|-------|
| Single gene focused (rule-based) | 0.68 seconds |
| Single gene comprehensive (rule-based) | 0.60 seconds |
| Single gene comprehensive (LLM-powered) | ~15 seconds |
| Multi-gene (5 genes, rule-based) | 15.49 seconds |
| Multi-gene (5 genes, LLM-powered) | ~62 seconds |
| Cross-cell comparison | <0.01 seconds |
| Cell types analyzed | 10 |
| Network cache load time | < 1 second |
| Reactome API latency | 0.3-1.5 seconds |

---

## DATA SOURCES & VALIDATION

### What This System Provides

**RegNetAgents is a hypothesis generation tool** that integrates:
1. Pre-computed regulatory networks from established methods (ARACNe networks from GREmLN team)
2. Curated pathway annotations (Reactome)
3. LLM-powered and rule-based domain analysis (cancer, drug, clinical, systems biology perspectives)

**Not a diagnostic tool**: All outputs are computational predictions requiring experimental validation.

### Data Provenance & Quality

**Regulatory Networks** (CellxGene Data Portal):
- **Source**: 500K+ single cells from CellxGene consortium datasets
- **Method**: ARACNe algorithm (mutual information-based network inference)
- **Coverage**: ~15,000-20,000 genes per cell type
- **Cell Types**: 10 networks (CD4/CD8 T cells, B cells, monocytes, NK cells, erythrocytes, epithelial, etc.)
- **Quality**: High-quality filtered single-cell data from peer-reviewed studies

**Pathway Annotations** (Reactome):
- **Curation**: Manually curated, peer-reviewed biological pathways
- **Statistical Testing**: Hypergeometric test to identify over-represented pathways
- **Multiple Testing Correction**: FDR < 0.05 (False Discovery Rate - controls for false positives when testing many pathways simultaneously)
- **Updates**: Real-time API ensures current annotations

### How Domain Agents Work

**Rule-Based Scoring Systems** (not machine learning models):

- **Cancer Agent**: Evaluates genes against cancer biology principles (Hanahan & Weinberg hallmarks of cancer). Uses network connectivity patterns to assess regulatory complexity and therapeutic targeting opportunities.

- **Clinical Agent**: Classifies biomarker types using FDA framework categories (diagnostic = detects disease; prognostic = predicts outcome; predictive = guides treatment). Scores based on network position and regulatory role.

- **Drug Agent**: Assesses therapeutic potential from network topology and connectivity patterns. Suggests intervention strategies based on upstream/downstream regulatory patterns.

- **Systems Agent**: Quantifies network centrality metrics to identify hub genes and predict perturbation cascades.

### Perturbation Analysis: Dual Ranking Approach

**Network Centrality Metrics** (NetworkX implementation):
- **Metrics Used**: PageRank, degree centrality, out-degree centrality
- **Computational Source**: Network science algorithms from Mora & Donaldson (2021)
- **Purpose**: Rank upstream regulators by predicted therapeutic impact

**Two Complementary Rankings Provided**:

1. **PageRank-Based Ranking** (Primary):
   - Measures influence via network diffusion dynamics
   - Best predictor of successful drug targets in literature
   - Captures indirect regulatory influence (multi-hop effects)
   - Example: TP53 regulators ranked â†’ WWTR1 > RBPMS > PRRX2 > CHD4 > THRA > YAP1 > IKZF2

2. **Out-Degree Centrality-Based Ranking** (Secondary):
   - Measures direct downstream connectivity (number of targets regulated)
   - Identifies regulators controlling largest gene cascades
   - Simple, interpretable metric for direct regulatory breadth
   - Example: TP53 regulators ranked â†’ RBPMS > WWTR1 > CHD4 > YAP1 > IKZF2

**Why Both Rankings?**
- **Different biological questions**: PageRank = network influence; Out-degree = cascade breadth
- **Complementary insights**: Some targets rank high on both (e.g., WWTR1, RBPMS for TP53)
- **Research flexibility**: Researchers can choose ranking based on experimental goals
- **Validation**: TP53 regulators WWTR1 and YAP1 (Hippo pathway) confirmed in literature

### System Validation Approach

**Case Study Validation** (Colorectal Cancer Biomarkers):
- 5 candidate genes analyzed: MYC, CTNNB1, CCND1, TP53, KRAS
- All 5 have published literature validating their CRC biomarker roles
- System classifications (diagnostic/prognostic/predictive) align with clinical use
- **Interpretation**: System produces biologically plausible hypotheses consistent with known biology

**What This Validates**:
- âœ“ Network data reflects established regulatory relationships
- âœ“ Pathway enrichment identifies relevant biological processes
- âœ“ Domain agent scoring correlates with literature-known gene functions

**What This Does NOT Validate**:
- âœ— Novel predictions (untested genes would require experimental validation)
- âœ— Network centrality rankings as experimentally verified drug targets
- âœ— Biomarker classifications as FDA-approved diagnostics
- âœ— Gene expression changes from perturbation (topology-based only)

### Appropriate Use Cases

**System is designed for**:
- âœ“ **Hypothesis generation**: Rapidly identify candidate genes and regulators for investigation
- âœ“ **Target screening**: Prioritize which genes/regulators to validate experimentally
- âœ“ **Network structure analysis**: Understand regulatory hierarchies and hub regulators
- âœ“ **Multi-gene comparative analysis**: Screen gene panels for biomarker prioritization
- âœ“ **Cross-cell-type pattern identification**: Identify tissue-specific vs. universal regulation
- âœ“ **Educational demonstrations**: Teaching regulatory network concepts
- âœ“ **Literature contextualization**: Rapidly integrate network context with research findings

**System is NOT designed for**:
- âœ— **Gene expression prediction**: Network topology analysis, not dynamical modeling
- âœ— **Clinical diagnosis or treatment decisions**: Research tool, not clinical decision support
- âœ— **Regulatory submissions**: Not validated for FDA/EMA regulatory purposes
- âœ— **Replacing experimental validation**: Generates hypotheses requiring wet-lab confirmation
- âœ— **Genes absent from networks**: Limited to genes in CellxGene single-cell datasets
- âœ— **Non-human organisms**: Currently human-only (could extend to other species)

---

## DISCUSSION

### Key Advantages

**1. Pre-Computed Network Architecture**
- ARACNe networks pre-computed from 500K+ single cells (GREmLN team)
- Network cache loads in <1 second (vs. hours for real-time inference)
- Enables 115-480Ã— speedup over traditional workflows
- Strategic design choice: prioritize query speed over dynamic network updates

**2. Parallel Multi-Agent Execution**
- 4 domain agents run simultaneously per gene
- Multiple perspectives analyzed in parallel (not sequential)
- 4-6x speedup from parallelization
- Async I/O for external API calls (Reactome)

**3. Workflow Automation**
- Adaptive analysis sequence based on gene characteristics
- Avoids unnecessary computation for simple queries
- Comprehensive mode triggers all domain analyses

**4. Domain-Specific Expertise**
- Cancer, drug, clinical, systems biology agents
- Specialized scoring algorithms per domain
- Integration of disparate analysis types

**5. Cell-Type Specificity**
- 10 regulatory networks (epithelial, immune, blood cell types)
- Cross-cell comparison identifies tissue-specific patterns
- Supports translational research questions

### Limitations & Future Work

**Current Limitations**:
- 10 cell types currently available (limited by available pre-computed networks)
- Networks updated periodically (not dynamic with each new dataset)
- Limited to human genes with Ensembl IDs (no cross-species support)

**Recent Additions**:
- âœ… **Perturbation Analysis**: Simulate regulator inhibition for therapeutic target identification
  - Ranks upstream regulators using network centrality metrics (PageRank, out-degree centrality)
  - Calculates cascade effects and network connectivity
  - Automated network-based perturbation simulation with dual ranking approaches

**Future Directions**:
- Expand cell type coverage as additional networks become available
- Integrate additional pathway databases (KEGG, GO, MSigDB)
- Optimize batch processing for large gene panels
- Enhance domain agent scoring algorithms
- Improve cross-cell comparison visualizations
- Add combination perturbation analysis (inhibit multiple regulators simultaneously)

### Impact

**Research Applications**:
- Biomarker discovery for diagnostics
- Drug target identification
- Disease mechanism elucidation
- Comparative genomics studies

**Clinical Translation**:
- Precision medicine decision support
- Clinical trial patient stratification
- Therapeutic intervention planning

---

## CONCLUSIONS

RegNetAgents demonstrates that **multi-agent AI frameworks** can effectively orchestrate complex gene regulatory network analyses across multiple biological domains. Key innovations include:

1. **Intelligent routing** that optimizes analysis paths based on gene characteristics
2. **Parallel execution** enabling second-scale analysis (0.6-62 sec depending on mode and genes analyzed)
3. **Domain-specific agents** providing specialized cancer, drug, clinical, and systems perspectives
4. **Cell-type specificity** supporting translational research questions

The framework successfully bridges computational biology, AI workflow orchestration (LangGraph), and conversational interfaces (local MCP server for Claude Desktop) to make sophisticated gene analysis accessible to researchers.

**Data Availability**: All regulatory network data obtained from publicly available sources: GREmLN Quickstart Tutorial (pre-computed ARACNe networks from GREmLN team), CZ CELLxGENE Data Portal (scRNA-seq data), Reactome API (pathway annotations), and MyGene.info API (gene annotations).

---

## TAKE HOME MESSAGE

**RegNetAgents transforms gene analysis from a multi-hour manual task into a second-scale conversational experience, enabling researchers to rapidly generate testable hypotheses for cancer biomarker discovery and experimental prioritization. Framework designed for hypothesis generation, not therapeutic claims.**

**ğŸ”¬ Second-Scale Analysis â€¢ Literature-Aligned Patterns â€¢ Natural Language Interface â€¢ Hypothesis Generation Tool**

---

## CONTACT

**Jose A. Bird, PhD**
Bird AI Solutions

**Email**: jbird@birdaisolutions.com
**LinkedIn**: https://www.linkedin.com/in/jose-bird-data-science-advanced-analytics/
**Learn More**: [QR Code to Poster Web Page]

*Interested in Gene Regulatory Agents for your research? Let's connect!*

---

## ACKNOWLEDGMENTS

### Data Sources
- **CellxGene Data Portal**: Chan Zuckerberg Initiative (single-cell RNA-seq datasets)
- **ARACNe Algorithm**: Califano Lab, Columbia University (network inference methodology)
- **Reactome Pathways**: Open access pathway database
- **MyGene.info**: NCBI-backed gene annotation service
- **License**: All data sources are publicly available under open licenses

### Gene Regulatory Agents Framework
Multi-agent orchestration layer built on top of pre-computed regulatory networks. Adds intelligent workflow routing, parallel gene analysis, LLM-powered domain-specific analysis agents (cancer, drug, clinical, systems biology using Ollama), and Model Context Protocol integration for conversational access via Claude Desktop.

**Key Distinction**: The pre-computed regulatory networks (derived from CellxGene data via ARACNe) provide the network topology; Gene Regulatory Agents provides the LLM-powered multi-agent AI analysis framework.

**Development Note**: This framework was developed with significant assistance from Claude Code (Anthropic's AI coding agent), demonstrating how AI-assisted development tools can enable researchers from diverse backgrounds to tackle complex computational challenges.

---

## REFERENCES

1. **GREmLN Foundation Model**: Zhang M, Swamy V, Cassius R, Dupire L, Karaletsos T, Califano A. (2025). GREmLN: A Cellular Regulatory Network-Aware Transcriptomics Foundation Model. bioRxiv. doi:10.1101/2025.07.03.663009

2. **CellxGene Data Portal**: Megill C, Martin B, Weaver C, et al. (2021). cellxgene: a performant, scalable exploration platform for high dimensional sparse matrices. bioRxiv. doi:10.1101/2021.04.05.438318

3. **ARACNe Algorithm**: Margolin AA, et al. (2006). ARACNE: An algorithm for the reconstruction of gene regulatory networks. BMC Bioinformatics.

4. **Reactome Database**: Gillespie M, et al. (2022). The reactome pathway knowledgebase 2022. Nucleic Acids Research.

5. **LangGraph Framework**: LangChain AI. Graph-based workflow orchestration for LLM applications.

6. **Model Context Protocol (MCP)**: Anthropic. Protocol for connecting AI assistants to external tools and data sources.

---

**Contact**: jbird@birdaisolutions.com

**Powered by**: LangGraph | MCP Protocol | Claude Desktop
